Alentis Therapeutics
CompanySwitzerland
Alentis Therapeutics develops one asset. Mostly antibody acting on CLDN1; based in Switzerland.
- 1
- Asset
- Furthest stage
- Not known
- 0
- Trials
- 1
- Signal
Pipeline
1Monoclonal antibody targeting Claudin-1
Stage not known, Antibody, CLDN1
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Signals1
- Similar companies1